AlphaCore Capital LLC Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)

Key Points

• AlphaCore Capital LLC increased its stake in Johnson & Johnson by 86.4% in Q1, owning 20,819 shares worth approximately $3.45 million as of its latest SEC filing.
• Several institutional investors have added to their positions, with 69.55% of the company's stock now held by institutional investors.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, representing an annualized dividend of $5.20 and a yield of 3.0%.

AlphaCore Capital LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 86.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,819 shares of the company's stock after acquiring an additional 9,650 shares during the quarter. AlphaCore Capital LLC's holdings in Johnson & Johnson were worth $3,453,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Lantz Financial LLC increased its holdings in Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after buying an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. purchased a new position in Johnson & Johnson in the 4th quarter worth approximately $453,000. Joel Isaacson & Co. LLC grew its stake in Johnson & Johnson by 3.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after buying an additional 2,526 shares in the last quarter. State of Wyoming grew its stake in Johnson & Johnson by 205,580.0% in the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after buying an additional 10,279 shares in the last quarter. Finally, Range Financial Group LLC grew its stake in Johnson & Johnson by 18.9% in the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock worth $2,635,000 after buying an additional 2,529 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

Johnson & Johnson stock traded up $1.87 during midday trading on Friday, hitting $173.40. The stock had a trading volume of 7,686,049 shares, compared to its average volume of 9,496,232. The firm's fifty day moving average is $159.26 and its two-hundred day moving average is $157.52. The company has a market capitalization of $417.61 billion, a PE ratio of 18.55, a P/E/G ratio of 2.21 and a beta of 0.41. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $173.96. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same period in the prior year, the firm posted $2.82 EPS. The firm's quarterly revenue was up 5.8% compared to the same quarter last year. On average, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.0%. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Barclays boosted their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Finally, UBS Group increased their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.